2 FTSE 100 stocks I’d buy in February and 1 I’d sell

Here are some of the stocks I’m buying and selling this month.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Every investor loves dividends. They’re the bread and butter of investing. Studies have shown that if you’re not investing with dividends in mind, you stand no chance of matching the market’s returns as around 50% of these come from reinvested dividends. 

That’s why I’m always hunting out the best dividend stocks and trying to avoid the worst, those dividend stocks that are clearly pursuing an unsustainable dividend policy.

Two top dividend picks 

BP (LSE: BP) and GlaxoSmithKline (LSE: GSK) are two dividend champions that look extremely attractive right now. Shares in these two companies both offer a dividend yield of 5% or more, and as we head into 2017, the outlook for both companies is improving.

This time last year, the price of Brent crude oil was around $41 a barrel. Today, the price is more than 25% higher at $54 a barrel, which is great news for BP. Over the past year, the company has been cutting costs to deal with the low oil price environment, and over the next 12 months, these actions should begin to pay off. 

Indeed, during 2017 City analysts expect the company’s earnings per share to grow by 153% and further earnings per share growth of 19% is pencilled-in for 2018. Based on these figures, the shares are trading at a 2017 forward P/E of 14.9 and support a dividend yield of 6.6%. 

Like BP, analysts are predicting strong earnings per share growth for Glaxo during 2017. Growth of 11% is pencilled-in for the year taking earnings to 112p, the highest level since 2012. Based on these estimates the shares are trading at a forward P/E of 14 and support a dividend yield of 5.2%. By 2017, Glaxo’s dividend payout will be covered 1.5 times by earnings per share.

One stock to avoid 

In comparison to Glaxo and BP, EasyJet (LSE: EZJ) looks to me to be a company to avoid during 2017. EasyJet’s advantage over its peers used to be the carrier’s low-cost model. However, over the past few years, this economic benefit has disappeared. 

As a result, City analysts are predicting a 28% decline in earnings per share for the fiscal year to 30 September 2017. These declines follow a 22% fall in earnings per share for 2016. For the year ending 30 September 2017, City analysts expect EasyJet report a pre-tax profit of £385m and earnings per share of 78p. For some comparison, two years ago EasyJet reported a record pre-tax profit of £686m and earnings per share of 139p. 

Even though the company’s dividend yield of 5.7%, is covered twice by earnings per share at present, this payout could come under pressure if earnings continue to decline. Shares in EasyJet currently trade at a forward P/E of 12.2, which looks appropriate considering the group’s rapidly declining profits. All in all, considering EasyJet’s flagging growth it may be best to avoid the company for the time being.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended BP. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

With a 10%+ dividend yield, is this overlooked gem the best FTSE 100 stock to buy now?

Many a FTSE 100 stock offers a good yield now, although that could change as the index rises. This one…

Read more »

Investing Articles

£10k in an ISA? I’d use it to aim for an annual £1k second income

Want a second income without having to take on a second job? With a bit of money up front, and…

Read more »

Investing Articles

Up over 100% in price in 10 years! Big Yellow also offers passive income from dividends

Oliver loves the look of Big Yellow to generate a healthy passive income from its generous dividends. He thinks storage…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

If I put £750 into a SIPP every month, could I retire a millionaire?

Ben McPoland considers a high-quality FTSE 100 stock that could contribute towards building him a large SIPP portfolio in future.

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »